Precigen (NASDAQ:PGEN) Hits New 52-Week High – What’s Next?

Precigen, Inc. (NASDAQ:PGEN)’s share price reached a new 52-week high during trading on Wednesday . The company traded as high as $1.97 and last traded at $1.86, with a volume of 1362520 shares changing hands. The stock had previously closed at $1.70.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Precigen in a research note on Thursday, January 23rd. JMP Securities reissued a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $7.00.

Precigen Stock Up 12.6 %

The firm has a market capitalization of $560.85 million, a P/E ratio of -3.48 and a beta of 1.66. The stock has a fifty day simple moving average of $1.08 and a 200 day simple moving average of $1.03.

Institutional Trading of Precigen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Iridian Asset Management LLC CT grew its position in shares of Precigen by 82.5% during the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after purchasing an additional 1,706,815 shares in the last quarter. LexAurum Advisors LLC boosted its stake in Precigen by 151.9% during the fourth quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock valued at $775,000 after buying an additional 417,055 shares during the last quarter. Geode Capital Management LLC grew its holdings in Precigen by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after buying an additional 149,829 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Precigen by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after acquiring an additional 127,467 shares during the last quarter. Finally, HighTower Advisors LLC raised its holdings in shares of Precigen by 186.8% during the 3rd quarter. HighTower Advisors LLC now owns 192,144 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 125,145 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.